GALT Stock Summary and Trading Ideas (Galectin Therapeutics | NASDAQ:GALT)

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics trades on the NASDAQ stock market under the symbol GALT.

As of December 26, 2025, GALT stock price climbed to $4.05 with 401,099 million shares trading.

GALT has a beta of 0.58, meaning it tends to be less sensitive to market movements. GALT has a correlation of 0.01 to the broad based SPY ETF.

GALT has a market cap of $261.14 million. This is considered a Small Cap stock.

In the last 3 years, GALT traded as high as $7.13 and as low as $.73.

The top ETF exchange traded funds that GALT belongs to (by Net Assets): VTI, VXF, IWC, MEDX, QQQS.

GALT has outperformed the market in the last year with a return of +381.8%, while the SPY ETF gained +16.0%. However, in the most recent history, GALT shares have underperformed the stock market with its stock returning -14.7% in the last 3 month period and -26.2% for the last 2 week period, while SPY has returned +4.7% and +0.7%, respectively.

GALT support price is $3.72 and resistance is $4.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GALT shares will trade within this expected range on the day.